Sunovion Pharmaceuticals Acquires Cynapsus Therapeutics for $841 Million
|Areas||Competition, Antitrust and Foreign Investment, Corporate and Commercial, Employment and Labour, Health Care Law, Intellectual Property , Litigation, Pensions, Tax|
Goodmans represented Suovian Pharmaceuticals Inc. (Sunovion) in connection with its acquisition by plan of arrangement of Cynapsus Therapeutics Inc. (Cynapsus) (NASDAQ: CYNA) (TSX: CTH) for approximately $841 million. The acquisition is aligned with Sunovion’s global strategy to expand and diversify its portfolio in key therapeutic areas, including neurology.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion is headquartered in Marlborough, Massachusetts and is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a leading Japanese pharmaceutical company.